157 related articles for article (PubMed ID: 8522350)
1. A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy.
Haisma HJ; Van Muijen M; Scheffer G; Scheper RJ; Pinedo HM; Boven E
Hybridoma; 1995 Aug; 14(4):377-82. PubMed ID: 8522350
[TBL] [Abstract][Full Text] [Related]
2. Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy.
Houba PH; Boven E; Haisma HJ
Bioconjug Chem; 1996; 7(5):606-11. PubMed ID: 8889024
[TBL] [Abstract][Full Text] [Related]
3. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
4. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM.
Cheng TL; Wu PY; Wu MF; Chern JW; Roffler SR
Bioconjug Chem; 1999; 10(3):520-8. PubMed ID: 10346886
[TBL] [Abstract][Full Text] [Related]
5. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
6. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs.
Cheng TL; Chen BM; Chan LY; Wu PY; Chern JW; Roffler SR
Cancer Immunol Immunother; 1997 Aug; 44(6):305-15. PubMed ID: 9298932
[TBL] [Abstract][Full Text] [Related]
7. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy.
Cheng TL; Chen BM; Chern JW; Wu MF; Roffler SR
Bioconjug Chem; 2000; 11(2):258-66. PubMed ID: 10725103
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.
Haisma HJ; van Muijen M; Pinedo HM; Boven E
Cell Biophys; 1994; 24-25():185-92. PubMed ID: 7736523
[TBL] [Abstract][Full Text] [Related]
9. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
10. Activation of human beta-glucuronidase by murine monoclonal antibodies and bovine serum albumin in an uncompetitive fashion.
Ho KJ
Biochem Mol Biol Int; 1995 Aug; 36(6):1277-86. PubMed ID: 8535300
[TBL] [Abstract][Full Text] [Related]
11. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
[TBL] [Abstract][Full Text] [Related]
12. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.
Haisma HJ; Sernee MF; Hooijberg E; Brakenhoff RH; vd Meulen-Muileman IH; Pinedo HM; Boven E
Blood; 1998 Jul; 92(1):184-90. PubMed ID: 9639515
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
[TBL] [Abstract][Full Text] [Related]
14. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
Sharma SK; Bagshawe KD; Burke PJ; Boden JA; Rogers GT; Springer CJ; Melton RG; Sherwood RF
Cancer; 1994 Feb; 73(3 Suppl):1114-20. PubMed ID: 8306255
[TBL] [Abstract][Full Text] [Related]
15. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Springer CJ; Niculescu-Duvaz I
Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
[TBL] [Abstract][Full Text] [Related]
16. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
[TBL] [Abstract][Full Text] [Related]
17. Conjugates of COL-1 monoclonal antibody and beta-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug beta-D-galactosyl-5-fluorouridine.
Abraham R; Aman N; von Borstel R; Darsley M; Kamireddy B; Kenten J; Morris G; Titmas R
Cell Biophys; 1994; 24-25():127-33. PubMed ID: 7736516
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy.
Chen BM; Cheng TL; Tzou SC; Roffler SR
Int J Cancer; 2001 Dec; 94(6):850-8. PubMed ID: 11745488
[TBL] [Abstract][Full Text] [Related]
19. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM
Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
